Investors

Media Room

In The News

May 29, 2023
NOTICE OF DEFAULT - UPDATE
May 15, 2023
NOTICE OF DEFAULT - UPDATE
May 9, 2023
AREV IMPLEMENTS AI AS A DRIVING FORCE TO IDENTIFY SCIENCE BACKED COMPOUNDS SYNERGISTIC TO ITS PROPRIETARY EXTRACTS TO INCREASE EFFICACY OF TRADITIONAL MEDICINE
April 27, 2023
AREV Life Sciences Global Corp. Announces Filing of Application for Management Cease Trade Order
March 27, 2023
AREV TERMINATES PRIVATE PLACEMENT AND TERM SHEET WITH FIBERLAB, Inc.
March 15, 2023
AREV Signs Term Sheet with Fiberlab, Inc.
February 28, 2023
AREV Life Sciences Provides Annual Review for 2022 and Operational Update
February 15, 2023
TEAM FROM QUEENSLAND BRAIN INSTITUTE IDENTIFIES NEW HERICERIN DERIVITIVES FROM LIONS MANE THAT BOOST NERVE GROWTH AND ENHANCES MEMORY
January 4, 2023
AREV Annual General Meeting Results - January 2023
January 6, 2023
Arev Board Change
January 12, 2023
AREV ISSUES INCENTIVE STOCK OPTIONS
November 8, 2022
AREV SIGNS TERM SHEET WITH SALT SPRING ISLAND BOTANAMED
October 28, 2022
Dr. Andrew Levinson Joins AREV Life Sciences Global Corporation Scientific Advisory Board
September 22, 2022
AREV NOTES U.S. GOVERNMENTS $2.9 BILLION ASSISTANCE TO ADDRESS FOOD INSECURITY
August 25, 2022
SUSTAINN, AREV’s Ready to Use Therapeutic Foods discussed in leading article in HealthHIV
August 17, 2022
AREV ADDS DR. APTE TO THE SAB
August 17, 2022
AREV CORPORATE UPDATE
August 10, 2022
AREV CORPORATE UPDATE
June 15, 2022
AREV Life Sciences announces acceleration of the clinical development of SUSTAINN, as further predictions of global famine increase demand for Ready to Use Therapeutic Foods (RUTF’s)
May 27, 2022
AREV Life Sciences issues retention warrants

Press Releases

May 29, 2023
NOTICE OF DEFAULT - UPDATE
May 15, 2023
NOTICE OF DEFAULT - UPDATE
May 9, 2023
AREV IMPLEMENTS AI AS A DRIVING FORCE TO IDENTIFY SCIENCE BACKED COMPOUNDS SYNERGISTIC TO ITS PROPRIETARY EXTRACTS TO INCREASE EFFICACY OF TRADITIONAL MEDICINE
April 27, 2023
AREV Life Sciences Global Corp. Announces Filing of Application for Management Cease Trade Order
March 27, 2023
AREV TERMINATES PRIVATE PLACEMENT AND TERM SHEET WITH FIBERLAB, Inc.
March 15, 2023
AREV Signs Term Sheet with Fiberlab, Inc.
February 28, 2023
AREV Life Sciences Provides Annual Review for 2022 and Operational Update
February 15, 2023
TEAM FROM QUEENSLAND BRAIN INSTITUTE IDENTIFIES NEW HERICERIN DERIVITIVES FROM LIONS MANE THAT BOOST NERVE GROWTH AND ENHANCES MEMORY
January 4, 2023
AREV Annual General Meeting Results - January 2023
January 6, 2023
Arev Board Change
January 12, 2023
AREV ISSUES INCENTIVE STOCK OPTIONS
November 8, 2022
AREV SIGNS TERM SHEET WITH SALT SPRING ISLAND BOTANAMED
October 28, 2022
Dr. Andrew Levinson Joins AREV Life Sciences Global Corporation Scientific Advisory Board
September 22, 2022
AREV NOTES U.S. GOVERNMENTS $2.9 BILLION ASSISTANCE TO ADDRESS FOOD INSECURITY
August 25, 2022
SUSTAINN, AREV’s Ready to Use Therapeutic Foods discussed in leading article in HealthHIV
August 17, 2022
AREV ADDS DR. APTE TO THE SAB
August 17, 2022
AREV CORPORATE UPDATE
August 10, 2022
AREV CORPORATE UPDATE
June 15, 2022
AREV Life Sciences announces acceleration of the clinical development of SUSTAINN, as further predictions of global famine increase demand for Ready to Use Therapeutic Foods (RUTF’s)
May 27, 2022
AREV Life Sciences issues retention warrants

Peer Reviewed Articles

May 28, 2021
The protective effect of eicosapentaenoic acid-enriched phospholipids from sea cucumber...
Download PDF
May 28, 2021
Medicinal and health benefit effects of functional sea cucumbers
Download PDF

Navigation

HomeAbout AREVPipelineLeadershipInvestors & MediaContact Us
Copyright © 2022 - AREV Life Sciences Global Corp. | Website Design by Latched